文献速递乳腺癌放疗

早期乳腺癌辅助治疗中外照射加速部分乳腺照射(APBI)的毒性:前瞻性随机研究

Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study.
PubMed 文献 · Radiat Oncol · 2024-02-03

这项前瞻性随机研究将部分乳腺切除术后早期乳腺癌患者等额随机分入外照射APBI组与中等低分割全乳照射(WBI)组,比较可行性、安全性、耐受性和美容效果。共分析84例患者(中位年龄64岁),中位随访37个月(范围21-45个月),APBI组急性不良事件显著更少,≥2级晚期皮肤毒性方面APBI组显著更优(p=0.026),乳腺区域晚期毒性WBI组61% vs APBI组17%,APBI组美容效果更有利。

要点

  • 外照射APBI组急性皮肤反应、局部及全身症状显著少于中等低分割WBI组。
  • ≥2级晚期皮肤毒性方面APBI组显著更优(p=0.026)。
  • 乳腺区域晚期毒性(变形、水肿、纤维化、疼痛)WBI组61% vs APBI组17%。

核心结论

  • 外照射APBI在早期乳腺癌辅助治疗中显示出比标准方案更好的可行性和更少的毒性。
  • 本研究证实了在每日临床实践中建立外照射APBI的证据水平。

研究设计与样本

  • 前瞻性随机研究,部分乳腺切除术后早期乳腺癌患者等额随机分入外照射APBI组与中等低分割WBI组。
  • 外照射技术采用锥形束CT导航至瘤床夹子、深吸气屏气技术、容积旋转调强放疗剂量施加、无均整器滤过光束及六自由度机器人治疗床。
  • 采用问卷、CTCAE标准和照片记录评估美容效果与毒性。
  • 共分析84例患者,中位年龄64岁,中位随访37个月(范围21-45个月)。
  • 试验注册号NCT06007118。

主要发现

  • 在中位随访37个月(范围21-45个月)内,APBI组在皮肤反应、局部及全身症状方面的急性不良事件显著更少。
  • ≥2级晚期皮肤毒性方面观察到有利于APBI组的显著差异(p=0.026)。
  • 影响生活质量和美容效果的乳腺区域晚期毒性(变形、水肿、纤维化、疼痛)在WBI组和APBI组的发生率分别为61%和17%。
  • APBI组美容效果更有利,尤其在放疗后6至12个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accelerated partial breast irradiation (APBI) is an alternative breast-conserving therapy approach where radiation is delivered in less time compared to whole breast irradiation (WBI), resulting in improved patient convenience, less toxicity, and cost savings. This prospective randomized study compares the external beam APBI with commonly used moderate hypofractionated WBI in terms of feasibility, safety, tolerance, and cosmetic effects. METHODS: Early breast cancer patients after partial mastectomy were equally randomized into two arms- external APBI and moderate hypofractionated WBI. External beam technique using available technical innovations commonly used in targeted hypofractionated radiotherapy to minimize irradiated volumes was used (cone beam computed tomography navigation to clips in the tumor bed, deep inspiration breath hold technique, volumetric modulated arc therapy dose application, using flattening filter free beams and the six degrees of freedom robotic treatment couch). Cosmetics results and toxicity were evaluated using questionnaires, CTCAE criteria, and photo documentation. RESULTS: The analysis of 84 patients with a median age of 64 years showed significantly fewer acute adverse events in the APBI arm regarding skin reactions, local and general symptoms during a median follow-up of 37 months (range 21-45 months). A significant difference in favor of the APBI arm in grade ≥ 2 late skin toxicity was observed (p = 0.026). Late toxicity in the breast area (deformation, edema, fibrosis, and pain), affecting the quality of life and cosmetic effect, occurred in 61% and 17% of patients in WBI and APBI arms, respectively. The cosmetic effect was more favorable in the APBI arm, especially 6 to 12 months after the radiotherapy. CONCLUSION: External APBI demonstrated better feasibility and less toxicity than the standard regimen in the adjuvant setting for treating early breast cancer patients. The presented study confirmed the level of evidence for establishing the external APBI in daily clinical practice. TRIAL REGISTRATION: NCT06007118.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Burkon P, Selingerova I, Slavik M, et al. Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study. Radiat Oncol. 2024. PMID: 38310249. doi:10.1186/s13014-024-02412-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。